Apotea AB (publ) (FRA:V30) Stock Based Compensation: €0.0 Mil (TTM As of Mar. 2026)


FRA:V30 Apotea AB (publ) FRA:V30
19 GF Score
Price €6.84
! 1 Warning Sign
View Full Analysis

What is Apotea AB (publ) Stock Based Compensation?

Apotea AB (publ) FRA:V30 +1.33% 19 Stock Based Compensation is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:V30 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Apotea AB (publ)'s Stock Based Compensation for the three months ended in Mar. 2026 was €0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Apotea AB (publ) Stock Based Compensation Related Terms

Apotea AB (publ) Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Apotea AB (publ)'s Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apotea AB (publ) Stock Based Compensation Chart

Apotea AB (publ) Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
0.00 0.00 0.00 0.00 0.00

Apotea AB (publ) Quarterly Data
Dec21 Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:V30
19GF Score
Apotea AB (publ) FRA:V30
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apotea AB (publ) Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

What does a Stock Based Compensation of €0.0 Mil mean?
Apotea AB (publ) (FRA:V30) has a Stock Based Compensation of €0.0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Apotea AB (publ) and its competitors.
Is Apotea AB (publ)'s Stock Based Compensation too high?
Apotea AB (publ)'s current Stock Based Compensation is €0.0 Mil. Overall, Apotea AB (publ) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s Stock Based Compensation compare to competitors?
Apotea AB (publ)'s Stock Based Compensation of €0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Healthcare Providers & Services company?
A good Stock Based Compensation depends on the Healthcare Providers & Services industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Apotea AB (publ) and its competitors. Apotea AB (publ)'s current Stock Based Compensation is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (FRA:V30) has a current Stock Based Compensation of €0.0 Mil. The current Stock Based Compensation is €0.0 Mil. Apotea AB (publ)'s overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Apotea AB (publ) (FRA:V30), the current Stock Based Compensation is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apotea AB (publ) Business Description

Other Exchanges APOTEA:SwedenV30:Germany
Address Sveavagen 168, Stockholm, SWE, 11346
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
19GF Score

Get the complete analysis for FRA:V30

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.84
Price